Profusa, Inc. Common Stock
A complete Wall Street Score is unavailable because required model components are missing. Missing model components: revenue, moat, financial, Buffett-style model component. These are scoring components, not a claim that the company has no assets or earnings. Missing inputs are not zero and do not by themselves make this a weak company. Available financial statements and source-backed research remain visible.
PFSA · Price history
Price at last available close
$0.77
−$1.21 (-61.07%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Profusa, Inc. Common Stock
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid.
How they make money
Profusa, Inc. is a biotechnology company focused on developing bioengineered sensors designed to detect and transmit clinical-grade data for personal and medical use. The company's business model centers on the research, development, and future commercialization of its proprietary sensor platforms, such as the Lumee Oxygen and Lumee Glucose systems, which are intended to monitor physiological parameters like tissue oxygen levels and glucose concentrations.
Products & services
The company develops the Lumee Oxygen Platform for monitoring compromised tissue in peripheral artery disease and chronic wounds, and the Lumee Glucose Platform for interstitial fluid glucose monitoring.
Brands & revenue mix
A platform designed to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery.
Separate brand revenue is not available in this research.Source
A platform designed to monitor glucose levels in interstitial fluid.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer categories were not separately identified in the reviewed source set.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
No supplier relationships were confirmed in the sources reviewed. This does not mean the company has no suppliers.
Risks
- The company has a history of operating losses and expects to incur significant expenses as it continues to develop and commercialize its products.Source
- The company's success depends on obtaining and maintaining regulatory approvals for its products in the United States and international markets.Source
Sources
Company-specific research
Questions worth answering for PFSA
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can PFSA fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is PFSA's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for PFSA to reach sustainable profitability?
- •What future growth or profitability would be needed to justify PFSA's current valuation?
- •What does the current share basis reconciled warning mean for the reliability or interpretation of PFSA's score?
Essential Investment Snapshot
Market Cap
$3.6M
P/E Ratio
-0.0
EPS
$-213.25
52-Week High
$3000.00
52-Week Low
$1.25
Beta
0.50
Shares Outstanding
1.1M
Total Debt
$14.0M
Dividend
No current dividend
Liquidation Value / Share
$-24.60
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for PFSA
Detected from reported data — verify before acting.Elevated debt risk
Negative shareholder equity • Interest coverage is below 2x • Cash covers less than 20% of total debt
Reverse-split headline · Aug 13, 2026
Profusa Announces 1-for-4 Reverse Stock Split — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on PFSA.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
Potential downside factors
- −Debt risk (elevated): Negative shareholder equity.
- −Interest coverage is below 2x.
- −Cash covers less than 20% of total debt.
- −The company has a history of operating losses and expects to incur significant expenses as it continues to develop and commercialize its products.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$0.77
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· |
| Cost of Revenue | $2K | $0.00 | $0.00 | $0.00 | ···· | ···· |
| Gross Profit | -$2K | $0.00 | $0.00 | $0.00 | ···· | ···· |
| Research & Development | $3.9M | $2.8M | $1.6M | $2.0M | ···· | ···· |
| SG&A Expenses | $27.9M | $24.9M | $3.0M | $4.1M | ···· | ···· |
| Operating Expenses | $31.8M | $13.2M | $4.5M | $6.1M | ···· | ···· |
| EBITDA | -$35.0M | -$30.7M | -$4.8M | -$6.0M | ···· | ···· |
| Operating Income | -$31.8M | -$13.2M | -$4.5M | -$6.1M | ···· | ···· |
| Interest Expense | $5.3M | $5.1M | $4.4M | $4.3M | ···· | ···· |
| Income Before Tax | -$43.0M | -$35.8M | -$9.2M | -$10.3M | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· |
| Net Income | -$43.0M | -$35.8M | -$9.2M | -$10.3M | ···· | ···· |
| Basic EPS | $-213.25 | $-107.01 | $-357.13 | $-76.65 | ···· | ···· |
| Basic Shares | 57.7K | 335K | 25.8K | 134K | ···· | ···· |
| Diluted Shares | 57.7K | 335K | 25.8K | 134K | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$151.80
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+36.1%
Cash Change
+8.5%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included EPS growth, cash levels. Pressure indicators included debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS increased 28.2%. Cash increased 8.5%. Total debt increased 36.1%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
Head to Head Review: OraSure Technologies (NASDAQ:OSUR) and Profusa (NASDAQ:PFSA)
Micro Cap Profusa Navigates European Regulatory Hurdles to Advance Oxygen Monitoring Tech
Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October
Profusa, Inc. Receives Nasdaq Compliance Determination
Rumor Mill · PFSA
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial